Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 11, 2019
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AM0010,Inapplicable
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
An Expanded Access Program for AM0010 (Pegilodecakin)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 13, 2018
Lead Product(s) : AM0010,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 26, 2017
Lead Product(s) : Interleukin 2,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 26, 2017
Lead Product(s) : Interleukin 2,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 22, 2017
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 30, 2017
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 05, 2016
Lead Product(s) : Interleukin 2,Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 12, 2013
Lead Product(s) : Interleukin 2,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
